Business Monitor International (BMI) has announced its latest report, China Pharmaceuticals & Healthcare Report.

The healthcare and pharmaceutical analysis includes Business Monitor International’s five and ten year forecast for drugs and healthcare expenditure, imports and exports, and focuses on the growth outlook for the prescription, OTC, patented drugs and generics market segments. The forecasts are based on in depth analysis into industry trends and new developments.

The China Analysis report is designed to provide industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Chinese pharmaceutical and healthcare industry. The report is vital to these groups so that they can benchmark BMI’s independent five and ten year pharmaceutical and healthcare industry forecasts on Chine, target business opportunities and risks in the Chinese pharmaceutical and healthcare sector and asses the activities, strategy and market position of pharmaceutical competitors, partners and clients.

Following the outcome of Q1 2011, BMI now predicts China will become the most attractive pharmaceutical market in Asia Pacific within the next five years. China has the world´s most attractive emerging pharmaceutical market. Driven by a booming economy and underpinned by political stability, demand for medicines, both generic and patented, will continue to increase. However – the key downside risk is further pricing pressures, which could intensify in the event of an economic slowdown.

Via EPR Network
More Financial press releases